Plan sponsors’ overall
satisfaction with their PBMs was 7.8 on a 1-10 scale in 2022, down from
8.2 last year, according to Pharmaceutical
Strategies Group’s 2022 Pharmacy Benefit Manager Customer Satisfaction
Report. The report was based on
surveys completed by 236 individuals representing employers, unions/Taft
Hartley plans, health plans and health systems that covered an estimated
76 million lives. Respondents reported a lower likelihood to recommend
their PBM to a colleague or to renew their contract without issuing a
competitive request for proposal this year, highlighting costs as the
primary driver to leave the PBM.
Among core PBM services, satisfaction was highest for
“offering competitive traditional drug discounts” and “meeting financial
guarantees.” As clinical and cost management programs play a key role in
reducing overall costs, 82% of respondents reported using utilization
management, while only 8% used gene therapy financial protection
programs.
|
No comments:
Post a Comment